Related Experiment Video
Updated: May 29, 2026
06:32
Assessing Respiratory Immune Responses to Haemophilus Influenzae
Published on: June 29, 2021
[Haemophilus influenzae type b vaccine].
Tomohiro Katsuta1, Akihiko Saitoh
1Department of Medical Specialties, National Center for Child Health and Development.
Nihon Rinsho. Japanese Journal of Clinical Medicine
|September 20, 2011
Summary
The Haemophilus influenzae type b (Hib) vaccine is safe and effective, now available in Japan. Efforts are underway to increase Hib vaccine coverage and reduce preventable diseases in children.
Area of Science:
- Immunology
- Vaccinology
- Public Health
Context:
- Haemophilus influenzae type b (Hib) vaccine is globally recognized for its safety and effectiveness, included in national immunization programs in over 120 countries.
- In Japan, the Hib vaccine was licensed in December 2008 but remained a voluntary vaccine, posing a financial burden for caregivers.
- To address this, payment coverage was initiated in November 2010 through local governments, funded by the national budget.
Purpose:
- To highlight the importance of increasing Haemophilus influenzae type b (Hib) vaccine coverage in Japan.
- To address the "vaccine gap" between Japan and other developed nations regarding Hib vaccination rates.
- To emphasize the need to reduce vaccine-preventable diseases in Japanese children through enhanced immunization strategies.
Summary:
- The Haemophilus influenzae type b (Hib) vaccine, proven safe and effective worldwide, was introduced in Japan in 2008.
- Financial barriers due to its voluntary status were addressed by government payment coverage initiated in 2010.
- This initiative aims to bridge the vaccination gap and decrease Hib-related diseases in Japanese children.
Impact:
- Increased vaccine coverage for Haemophilus influenzae type b (Hib) can significantly reduce the incidence of severe infections in children.
- Addressing financial concerns through public funding is crucial for equitable access to essential vaccines.
- Closing the "vaccine gap" aligns Japan with global public health standards, protecting its pediatric population.
More Related Videos
13:47Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens
Published on: May 19, 2020
06:34An Optimized Hemagglutination Inhibition (HI) Assay to Quantify Influenza-specific Antibody Titers
Published on: December 1, 2017
Related Concept Videos
01:22Bacterial Meningitis I: Introduction
Bacterial meningitis is a severe, life-threatening inflammation of the meninges, particularly the pia mater and arachnoid mater, affecting the subarachnoid space, ventricles, and cerebrospinal fluid (CSF). If untreated, it can lead to significant neurological complications or death.Causative AgentsCommon pathogens vary with age and immune status. In adults, major organisms include Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae. Streptococcus agalactiae (group B...
01:51Vaccinations
Overview
01:28Diphtheria
Diphtheria is an acute, toxin-mediated infectious disease that primarily affects the upper respiratory tract. It is caused by Corynebacterium diphtheriae, a Gram-positive, pleomorphic rod that lacks spore-forming capability and exhibits a characteristic club-shaped morphology under microscopic examination. While C. diphtheriae can asymptomatically colonize mucosal surfaces, clinical disease manifests only when the bacterial strain is lysogenized by a specific β-corynephage. This phage...
01:24Bacterial Meningitis
Bacterial meningitis is a severe infectious disease involving inflammation of the meninges, the protective membranes surrounding the brain and spinal cord. It occurs when pathogenic bacteria cross the blood–brain barrier and enter the cerebrospinal fluid. Common causative organisms include Neisseria meningitidis, Streptococcus pneumoniae, Haemophilus influenzae type b, Listeria monocytogenes, and Escherichia coli K1. The exact route of entry varies by pathogen and host condition.Routes of Entry...
01:17Poliomyelitis
Poliomyelitis is caused by poliovirus, a small, non-enveloped, positive-sense RNA virus of the Picornaviridae family and Enterovirus genus. Transmission occurs primarily via the fecal-oral route, often through ingestion of contaminated water or food. The virus initially replicates in the oropharynx and intestinal mucosa, particularly in lymphoid tissues such as the tonsils, Peyer’s patches, and regional lymph nodes. Primary viremia follows, allowing dissemination throughout the body.In most...
01:26Bacterial Meningitis II: Pathophysiology
Bacterial meningitis typically begins when pathogens such as Neisseria meningitidis and Streptococcus pneumoniae colonize the nasopharynx and invade the bloodstream. This process is facilitated by bacterial virulence factors, such as polysaccharide capsules, which resist phagocytosis and complement-mediated killing. Less commonly, bacteria reach the central nervous system via contiguous spread from infections like otitis media or sinusitis, through congenital or acquired dural defects, or...